Glofitamab With Gemcitabine/Oxaliplatin Improves Survival in Transplant-Ineligible R/R DLBCL
Updated data from the phase 3 STARGLO study (NCT04408638) demonstrated that fixed-duration glofitamab-gxbm (Columvi) plus gemcitabine/oxaliplatin significantly improved both progression-free and overall survival (OS) compared with rituximab (Rituxan) …